Every 10-Q that L A M Y (LMMY) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow LMMY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LMMY filings page.
Exousia Bio, Inc. (LMMY) reports a transitional quarter marked by a shift from a small education venture to a clinical-stage oncology biotechnology business through its acquisition of Exousia AI. The deal added recorded “Other Assets” of $22,050,000 and drove total assets to $22,050,670 as of February 28, 2026.
The company generated no revenue in the three- or nine‑month periods and recorded a nine‑month net loss of $50,897, despite a $217,922 gain on acquisition. Research and development expenses reached $161,426, reflecting the new biotech focus.
Liquidity is very limited: Exousia Bio had no cash, current liabilities of $261,023 and a working‑capital deficit of $261,023, with an accumulated deficit of $288,623. A $250,000 convertible note at 15% interest matured on March 26, 2026 without available cash for repayment and carries steep post‑maturity conversion discounts, raising material dilution risk. Management discloses “substantial doubt” about the company’s ability to continue as a going concern.
Exousia Bio (still trading as L A M Y / LMMY) used this 10-Q to document a major pivot and ongoing financial strain. In November 2025 it acquired Exousia AI, a clinical-stage biotechnology company focused on exosome-based oncology therapies, by issuing 62,223,000 common shares.
For the six months ended November 30, 2025, the company reported no revenue and a net loss of $50,897, driven by $206,711 of operating expenses, including higher research and development and professional fees, partly offset by a $217,922 gain on the Exousia AI acquisition. Management discloses an accumulated deficit of $288,623 and explicitly raises substantial doubt about its ability to continue as a going concern without new capital.
As of November 30, 2025, 70,000,000 common shares were issued and outstanding, up from 7,777,000 at May 31, 2025, reflecting the reverse-merger structure. Subsequent events include authorizing preferred stock, changing the corporate name to Exousia Bio, cancelling 21,000,000 previously issued shares under a rescission agreement, issuing 3,500,000 shares to a consultant, and entering a $250,000 15% convertible note with GBII Partners Inc. that allows conversion at a significant discount to market, subject to a 4.999% beneficial ownership cap.
LAMY filed its quarterly report for the three months ended August 31, 2025, showing it remains a development-stage company with no operating revenue. The company reported a net loss of $31,814 for the quarter, compared with a net loss of $3,911 in the same period of 2024, driven mainly by professional fees, OTC market fees, and advertising expenses. As of August 31, 2025, LAMY reported total assets of $0 and total liabilities of $35,314, all current and largely due to related-party advances, resulting in a stockholders’ deficit of $35,314. The accumulated deficit since inception reached $63,584, and management states there is substantial doubt about the company’s ability to continue as a going concern. LAMY has 7,777,000 common shares outstanding and plans to rely on equity and/or debt financing and continued related-party support to fund operations, with no committed financing arrangements in place.